BRANDO, Chiara
 Distribuzione geografica
Continente #
NA - Nord America 1.918
EU - Europa 1.409
AS - Asia 1.235
SA - Sud America 230
AF - Africa 43
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 2
Totale 4.840
Nazione #
US - Stati Uniti d'America 1.849
SG - Singapore 530
RU - Federazione Russa 526
IT - Italia 366
CN - Cina 244
BR - Brasile 194
HK - Hong Kong 140
VN - Vietnam 123
DE - Germania 118
PL - Polonia 76
FR - Francia 74
GB - Regno Unito 69
FI - Finlandia 66
CA - Canada 39
IN - India 36
BD - Bangladesh 30
JP - Giappone 30
NL - Olanda 22
KR - Corea 18
IQ - Iraq 16
MX - Messico 14
ES - Italia 13
IE - Irlanda 13
ZA - Sudafrica 11
SE - Svezia 10
AT - Austria 9
RO - Romania 9
TR - Turchia 9
UA - Ucraina 9
NP - Nepal 7
PK - Pakistan 7
EC - Ecuador 6
ID - Indonesia 6
KE - Kenya 6
MA - Marocco 6
AE - Emirati Arabi Uniti 5
AR - Argentina 5
AZ - Azerbaigian 5
CO - Colombia 5
EG - Egitto 5
LT - Lituania 5
UY - Uruguay 5
BE - Belgio 4
IR - Iran 4
KZ - Kazakistan 4
MY - Malesia 4
PE - Perù 4
PH - Filippine 4
TT - Trinidad e Tobago 4
UZ - Uzbekistan 4
BO - Bolivia 3
CH - Svizzera 3
CI - Costa d'Avorio 3
CL - Cile 3
DZ - Algeria 3
JM - Giamaica 3
TN - Tunisia 3
VE - Venezuela 3
XK - ???statistics.table.value.countryCode.XK??? 3
AU - Australia 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
ET - Etiopia 2
GR - Grecia 2
LV - Lettonia 2
MM - Myanmar 2
PA - Panama 2
PS - Palestinian Territory 2
PT - Portogallo 2
PY - Paraguay 2
AL - Albania 1
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
CR - Costa Rica 1
DJ - Gibuti 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GE - Georgia 1
GH - Ghana 1
GT - Guatemala 1
HU - Ungheria 1
JO - Giordania 1
LA - Repubblica Popolare Democratica del Laos 1
MD - Moldavia 1
NG - Nigeria 1
NI - Nicaragua 1
PR - Porto Rico 1
RS - Serbia 1
SV - El Salvador 1
TH - Thailandia 1
VC - Saint Vincent e Grenadine 1
Totale 4.840
Città #
Ashburn 388
Singapore 318
San Jose 186
Chandler 132
Hong Kong 124
Moscow 104
Rome 87
Palermo 83
Fairfield 71
Los Angeles 64
Zgierz 64
New York 61
Helsinki 54
The Dalles 51
Beijing 44
Santa Clara 43
Council Bluffs 41
Ho Chi Minh City 38
Hefei 37
Houston 37
Dallas 32
Lauterbourg 32
Hanoi 28
Medford 28
Chicago 27
Tokyo 27
Woodbridge 27
Seattle 26
Frankfurt am Main 25
Buffalo 22
Milan 22
Wilmington 22
Boardman 19
São Paulo 17
Des Moines 15
Lawrence 15
Ludwigshafen am Rhein 15
Princeton 15
San Diego 14
Atlanta 13
London 13
Nuremberg 13
Orem 13
Altamura 12
Dublin 12
Montreal 11
Warsaw 11
Denver 10
Johannesburg 10
Lappeenranta 10
Seoul 10
Toronto 10
Ann Arbor 9
Bexley 9
Bremen 9
Brooklyn 9
Kitzingen 9
Stockholm 8
Boston 7
Cambridge 7
Falkenstein 7
Manchester 7
Phoenix 7
Pune 7
Rio de Janeiro 7
Central 6
Guangzhou 6
Mumbai 6
Nairobi 6
Poplar 6
Redondo Beach 6
Tappahannock 6
Vienna 6
Baku 5
Brasília 5
Chennai 5
Dhaka 5
Montevideo 5
Munich 5
Padova 5
Quảng Ngãi 5
San Francisco 5
Volla 5
Amsterdam 4
Baghdad 4
Belo Horizonte 4
Brussels 4
Cagliari 4
City of London 4
Kilburn 4
Mexico City 4
Paris 4
Philadelphia 4
Quito 4
Roubaix 4
Salt Lake City 4
Santa Catarina 4
Tampa 4
Tashkent 4
Tianjin 4
Totale 2.871
Nome #
BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients 230
A “lymphocyte microrna signature” as predictive biomarker of immunotherapy response and plasma pd-1/pd-l1 expression levels in patients with metastatic renal cell carcinoma: Pointing towards epigenetic reprogramming 222
Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions 218
Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2 215
BRCA1/2 variants of unknown significance in hereditary breast and ovarian cancer (HBOC) syndrome: Looking for the hidden meaning 193
Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors 182
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window? 178
Not all KIT 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs) 177
KIT/PDGFRA Variant Allele Frequency as Prognostic Factor in Gastrointestinal Stromal Tumors (GISTs): Results From a Multi-Institutional Cohort Study 174
MUTYH-associated tumor syndrome: The other face of MAP 173
POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes 169
Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge 165
Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay 162
Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer 157
Potential agnostic role of BRCA alterations in patients with several solid tumors: One for all, all for one? 157
Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors 155
Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab 149
Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors? 149
BRCA functional domains associated with high risk of multiple primary tumors and domain-related sensitivity to olaparib: the Prometheus Study 146
Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome 145
Impact of Different Selection Approaches for Identifying Lynch Syndrome-Related Colorectal Cancer Patients: Unity Is Strength 142
BRCA-associated hereditary male cancers: can gender affect the prevalence and spectrum of germline pathogenic variants? 136
Can circulating PD-1, PD-L1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels enhance prognostic power of CA125 in patients with advanced high-grade serous ovarian cancer? 134
Anthracycline-related cardiotoxicity in patients with breast cancer harboring mutational signature of homologous recombination deficiency (HRD) 130
Prognostic role of plasma pd‐1, pd‐l1, pan‐btn3as and btn3a1 in patients affected by metastatic gastrointestinal stromal tumors: Can immune checkpoints act as a sentinel for short‐term survival? 130
Clinical relevance of exosome-derived microRNAs in Ovarian Cancer: Looking for new tumor biological fingerprints 125
The intersection of homologous recombination (HR) and mismatch repair (MMR) pathways in DNA repair-defective tumors 123
Scientific Communication and oncology – "The bridge between knowledge and patients" 122
Prognostic and Predictive Role of Tumor-Infiltrating Lymphocytes (TILs) in Ovarian Cancer 117
Liquid biopsy and immunotherapy: is all that glitter gold? 109
Role of the HIPPO pathway as potential key player in the cross talk between oncology and cardiology 95
POTENTIAL APPLICATIONS OF LIQUID BIOPSY IN IMMUNOTHERAPY: ROLE OF EXOSOMES, MICRORNAS AND PLASMA EXPRESSION LEVELS OF IMMUNE CHECKPOINTS IN PATIENTS WITH SOLID TUMORS 94
POLE-mutated endometrial cancer: new perspectives on the horizon? 78
Totale 5.051
Categoria #
all - tutte 19.630
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.630


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022202 13 13 3 0 26 7 8 15 14 24 39 40
2022/2023363 28 64 10 48 40 41 16 37 32 4 27 16
2023/2024420 14 31 19 38 22 77 51 53 4 39 18 54
2024/20251.054 7 79 81 41 50 61 175 96 44 177 110 133
2025/20262.808 278 101 194 268 317 449 403 262 188 164 79 105
2026/202733 33 0 0 0 0 0 0 0 0 0 0 0
Totale 5.051